17-alpha-Estradiol
Alfatradiol
17-alpha-Estradiol (Alfatradiol) is a longevity & bioregulators research compound. A stereoisomer of estradiol that is essentially non-feminising — it barely activates the classical estrogen receptors, which is precisely why it's interesting. Topically it inhibits 5-alpha-reductase locally in the scalp. Systemically, in rodents, it extends lifespan in males without the feminising effects that make estradiol a non-starter.
17-alpha-Estradiol quick facts
| Reported research dose | 8mg-12mg (scaled) / topical 0.025-0.1% |
| Route | Topical (hair) / oral in rodent studies |
| Frequency | 1x Daily (topical) |
| Half-life | Varies by route |
| Forms | Oral, Topical |
| Evidence level | Rodent lifespan (ITP); topical human use for hair loss in Europe |
Two completely separate stories under one name. The topical version (alfatradiol) is used for androgenetic alopecia in parts of Europe with modest evidence. The longevity story is rodent-only, male-specific, and the human dose is unknown. Don't conflate them — a topical scalp product tells you nothing about systemic safety.
How 17-alpha-Estradiol works
A stereoisomer of estradiol that is essentially non-feminising — it barely activates the classical estrogen receptors, which is precisely why it's interesting. Topically it inhibits 5-alpha-reductase locally in the scalp. Systemically, in rodents, it extends lifespan in males without the feminising effects that make estradiol a non-starter.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
✅ Clinically validated
- No human longevity trials. What exists in humans is old dermatology work — it has been used topically for hair loss in Europe, at doses and routes with no relationship to the longevity use.
📊 Correlative data
- The animal result is unusually strong and unusually specific. The NIA Interventions Testing Program — the most rigorous lifespan programme there is, run across three independent sites — found it extended median lifespan in male mice only, with no effect in females.
- Human longevity use is minimal and recent. The sex-specific finding has no human counterpart at all.
🧪 Theoretical / extrapolated
- A non-feminising stereoisomer of estradiol — it has roughly 1/100th the affinity for the classical nuclear estrogen receptor, so it produces metabolic effects without the feminising ones that make 17-beta-estradiol unusable in men.
- Proposed to act through membrane-bound estrogen receptors and to reduce hepatic inflammation and improve insulin sensitivity.
- The male-only effect is the most informative fact about it. It suggests the benefit works by shifting male metabolic ageing toward a female-typical pattern — which predicts, correctly, that there is nothing left to gain in females. Very few interventions have a mechanism that explains their own limits this cleanly.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
17-alpha-Estradiol — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a sceptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a sceptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Where to get 17-alpha-Estradiol
See vetted vendors for 17-alpha-Estradiol →17-alpha-Estradiol — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What 17-alpha-Estradiol moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- Complete Blood Count (CBC) with Differential — ↑ expected to rise
Haematocrit and haemoglobin rise — androgens stimulate erythropoiesis. This is the most reliably predictable movement of any compound in the Vault.
What to do: This is the number that decides whether you keep going. Baseline and every 3 months. Dehydration on the draw day inflates it, so hydrate normally or you will chase a false reading. - Total Testosterone — ↑ expected to rise
Expected. Trough vs peak matters enormously — the same protocol reads completely differently depending on when you drew.
What to do: Draw at the same point in the cycle every time or the trend is noise. - LH & FSH — ↓ expected to fall
Suppressed by negative feedback. This is the mechanism, not a side effect — and it is why exogenous androgen shuts down your own production.
What to do: Relevant if fertility matters to you. Worth knowing before, not after. - Estradiol, Sensitive (LC/MS-MS) — ↑ expected to rise
Aromatisation converts a fraction to estradiol, and it rises with the androgen. Use the sensitive (LC-MS/MS) assay — the standard immunoassay is unreliable in men and produces numbers people then medicate.
What to do: If you are reading estradiol in a man, the assay choice matters more than the result. - SHBG (Sex Hormone-Binding Globulin) — ↓ expected to fall
Falls with androgen exposure, which raises the free fraction — so free testosterone can climb faster than total.
What to do: Read total and SHBG together; total alone understates what changed. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to worsen
HDL falls, sometimes markedly. Oral 17-alpha-alkylated compounds do this far more aggressively than injectable esters.
What to do: Baseline and 12 weeks. ApoB is the better long-term read than LDL-C. - PSA (Total + Free + % Free) — ↑ expected to rise
Androgens can raise PSA modestly. It does not create prostate cancer that wasn't there, but it can unmask it.
What to do: Baseline before starting matters — without it, a later number has nothing to be compared against.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for 17-alpha-Estradiol — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- How the forms differ in dose
- Coach Cam's personal notes
Get the complete breakdown for 17-alpha-Estradiol — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →Bloodwork to run alongside 17-alpha-Estradiol
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 102 markers A–Z
17-alpha-Estradiol — frequently asked questions
What is 17-alpha-Estradiol?
17-alpha-Estradiol (Alfatradiol) is a longevity & bioregulators research compound. A stereoisomer of estradiol that is essentially non-feminising — it barely activates the classical estrogen receptors, which is precisely why it's interesting. Topically it inhibits 5-alpha-reductase locally in the scalp. Systemically, in rodents, it extends lifespan in males without the feminising effects that make estradiol a non-starter.
Is the full 17-alpha-Estradiol protocol on this page?
The reported research dose is on this page, along with how 17-alpha-Estradiol works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside the Academy.
What is the half-life of 17-alpha-Estradiol?
17-alpha-Estradiol has an approximate half-life of Varies by route, which is part of what determines how often it's dosed.
What forms does 17-alpha-Estradiol come in?
17-alpha-Estradiol is available as: Oral, Topical.
What's the evidence behind 17-alpha-Estradiol?
Current evidence level: Rodent lifespan (ITP); topical human use for hair loss in Europe. 17-alpha-Estradiol is offered for research purposes only and is not an approved medicine.
Want Coach Cam's exact 17-alpha-Estradiol protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →What 17-alpha-Estradiol is used for
17-alpha-Estradiol appears under 1 goal in the Vault’s goal router, grouped by the mechanism it works through rather than by how much trial evidence exists. Each link opens that pathway in full, with the alternatives beside it and the bloodwork that tests it.